Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

UAC will study the possibility of SSJ100 production in India

2/14/23 UNAC

Ozon will build a distribution and storage center in the SEZ in Orenburg

2/14/23 OZON

Sber entered the market for smart health devices

2/14/23 SBER

VTB intends to launch an online bank in VKontakte and Odnoklassniki

2/14/23 VTBR

VK moves to russian jurisprudence

2/14/23 VKCO

Rusagro invests ₽4.7 billion in plants in the Saratov region

2/14/23 RAGR

Velodyne Lidar has teamed up with Ouster

2/14/23 VLDR

Tinkoff began to provide brokerage services

2/14/23 T

Palantir Technologies reports for 2022

2/14/23 PLTR

SolarEdge's 2022 revenues are up 58% and profits are down 45%

2/14/23 SEDG